A series of compounds structurally related to aripiprazole (1), an atypical antipsychotic and antidepressant used clinically for the treatment of schizophrenia, bipolar disorder, and depression, have been prepared and evaluated for affinity at D 2-like dopamine receptors. These compounds also share structural elements with the classical D 2-like dopamine receptor antagonists, haloperidol, N-methylspiperone, domperidone and benperidol. Two new compounds, 7-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one oxalate (6) and 7-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one oxalate (7) were found to (a) bind to the D 2 receptor subtype with high affinity (K i values <0.3 nM), (b) exhibit >50-fold D 2 versus D 3 receptor binding selectivity and (c) be partial agonists at both the D 2 and D 3 receptor subtype.
Introduction
Dopamine receptors belong to a large superfamily of neurotransmitter and hormone receptors which are coupled to their specific effectors function via guanine nucleotide regulatory (G) proteins. Based upon genomic and cDNA cloning studies, it is currently thought that there are five functionally active dopamine receptor subtypes expressed in mammals. These five receptor subtypes have been classified into two major types (D 1-like The D 2 and D 3 dopamine receptor subtypes are structurally and pharmacologically similar. 4 Despite these similarities, the D 2 and D 3 receptors differ in the neuroanatomical localization, the levels of receptor expression, efficacy in response to agonist stimulation, regulation, desensitization and the intracellular trafficking properties. [5] [6] [7] [8] Because of the high degree of homology between D 2 and D 3 receptor binding sites, it has been difficult to develop compounds that can selectively stimulate or block D 2 or D 3 receptors. 3, 6, 7, [9] [10] [11] This has also been true for the development of radiotracers for imaging dopamine D 2 and D 3 receptors with the functional imaging technique positron emission tomography or PET. That is, all radiotracers used in PET imaging studies bind with similar affinity to D 2 and D 3 receptors, and receptor density measurements using radiotracers such as the antagonists [ 11 2 in order to gain a better insight into the behavioral pharmacology and in vivo regulation of these structurally-similar dopamine receptors in disorders of the central nervous system. Previously, our group synthesized a series of ((1H-indol-3-yl)methyl)piperidin-4-ol analogs and evaluated their affinities and intrinsic activities for dopamine D 2 and D 3 receptors. These compounds share structural elements with the classical D 2-like dopamine receptor antagonists, haloperidol, N-methylspiperone and benperidol. Several of the compounds structurally similar to haloperidol were found to have moderate to high affinity and selectivity at D 2 versus D 3 receptors. 15, 16 Functional assays revealed that these compounds were antagonists at D 2 receptors. 15, 16 Aripiprazole, Fig. 1 ) has been used for the treatment of schizophrenia and various forms of depression. Aripiprazole has been reported to be an antagonist of postsynaptic dopamine receptor while acting as an agonist of dopamine autoreceptors. 17 Using aripiprazole as a lead compound, we synthesized a series of new compounds and evaluated their binding affinities and intrinsic activities at D 2-like receptors. These modifications include: (a) replacing the N-2,3-dichlorophenyl piperazine ring of aripiprazole with amine groups present in typical antipsychotics (haloperidol, benperidol, domperidone and N-methylspiperone), (b) replacing the N-2,3-dichlorophenyl group of aripiprazole with N-methoxyphenyl, or N-2-fluoroethoxy groups, (c) changing the length of the carbon atom spacer between the oxygen and nitrogen atoms, and, (d) introduction of a double bond into the 3,4-dihydro-2(1H)-quinolinone ring. The goal of this study is to modify the structure of aripiprazole in order to determine if it is possible to identify ligands having a higher affinity and selectivity for D 2 versus D 3 receptors for behavioral pharmacology and PET imaging studies.
Chemistry
The syntheses of all target compounds ( Fig. 2 ) are outlined in Schemes 1-4. Compounds 2-10 were prepared as outlined in Scheme 1. Starting from the commercially available 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1H)-one (20) and the corresponding piperidines or piperazines, the desired compounds 2-6, 8-10 and the intermediate 17 18 were obtained in 67-96% yields. Subsequently, fluoroethylation of the aromatic hydroxyl group of 17 with 1-bromo-2-fluoroethane gave 7 in 59% yield. The piperazine 19 was prepared from 2-methoxy-4-methylaniline (18) and bis-(2-chloroethyl)amine hydrochloride in the presence of potassium carbonate in butanol. 19 Compound 11 was synthesized from 7-(4-bromobutoxy)quinolin-2(1H)-one (21) 17 and 1-(2-methoxyphenyl)piperazine, whereas First, a comparison was made of the affinity at D 2 and D 3 dopamine receptors of the compounds which have structural elements similar to haloperidol, benperidol, domperidone, and N-methylspiperone. Surprisingly, these structural elements did not appear to have an effect on D 2-like receptor affinity or selectivity, with compounds 2-5 displaying weak affinity for D 2 , D 3 , and D 4 receptors. Next, a comparison of substituents at the piperazine moiety of aripiprazole was made in which the 2,3-dichloro substitution pattern of aripiprazole was replaced with either a 2-OCH 3 (compound 6) or a 2-OCH 2 CH 2 F (compound 7) group. We found that both methoxy and 2-fluoroethoxy groups resulted in a 2-fold decrease in affinity at D 3 receptors with a concomitant 14-and 12-fold increase in affinity at D 2 receptors, with compounds 6 and 7 having a 60-and 52-fold selectivity at D 2 receptors, respectively. This level of binding selectivity is 25 to 30 times greater than the lead compound aripiprazole (Table 1 ). Compounds 6, 7, 11, and 12, which contain a piperazine moiety and a saturated four carbon chain, exhibited the greatest affinity (K i values 0.07-0.26 nM, Table 1 ) and selectivity (39-to 60-fold) at D 2 receptors compared to the D 3 receptor subtype. The positions of the substituents at the piperazine moiety were also compared. Changing the methoxy group from the 2-position on the benzene ring (compound 6) to the 4-position (compound 8) decreased both D 2 and D 3 receptors affinity. Substitution on both 2-and 4-positions (compounds 9 and 10) decreased D 3 receptor affinity but had little effect on D 2 receptor affinity. Decreasing (compounds 13 and 14) or increasing (compounds 15 and 16) the length of the four carbon spacer by one carbon atom decreased D 2 receptor affinity, while having little to no effect on D 3 receptor affinity, thereby reducing the receptor subtype binding selectivity ( Table 1 , Fig. 2 ). Introduction of a double bond into the 3,4-dihydro-2(1H)-quinolinone ring had little effect on both D 2 and D 3 receptors affinity (compounds 11, 12, 14 and 16).
Adenylyl cyclase studies with D 2-like receptors
The pharmacological properties of the two compounds with the highest binding selectivity for D 2 dopamine receptors (6 and 7) were further evaluated using a whole cell forskolin-dependent adenylyl cyclase inhibition assay. The intrinsic efficacy of these compounds were compared to the full agonist quinpirole, as previously described. 15 Compounds 6 and 7 were found to be partial agonists at both D 2 and D 3 dopamine receptors. The intrinsic efficacy was found to be slightly greater (16-75%) at D 2 receptors compared to D 3 receptors. The intrinsic efficacy of these two compounds at human D 2 receptors is similar to that found for the lead compound aripiprazole, while the efficacy at D 3 receptors was somewhat lower (Fig. 3 ).
Radioligand binding studies at sigma receptors
In vitro binding studies were conducted to determine the affinity of the target compounds at sigma-1 (r 1 ) and sigma-2 (r 2 ) receptors. Since many structurally-diverse ligands are capable of binding to sigma receptors, we routinely screen our potential CNS PET radiotracers for binding affinity to r 1 and r 2 receptors. Any compound which binds with high affinity to r 1 and/or r 2 receptors would not be an appropriate candidate for the development of a dopaminergic PET imaging agent since sigma receptors are expressed ubiquitously in the CNS.
The r 1 binding studies were conducted using the r 1 -selective radioligand, [ 24, 25 The affinity at r 1 receptors varied from 150 to >20,000 nM. All of the compounds in this study bound with low affinity (>200 nM) at r 2 receptors. The affinity of the two compounds with the greatest D 2 receptor selectivity (6 and 7) bound to sigma receptors with low affinity (K i values >500 nM).
Discussion
The dopaminergic system has been the most thoroughly studies CNS receptor system using the functional imaging technique, PET. By-and-large, most imaging studies have been conducted using the radiotracer [ 11 28 These data were consistent with 6-OHDA and MPTP lesioning studies in animal models of PD. 29, 30 Therefore, D 2 and D 3 receptors appear to be regulated in an opposing manner in response to the loss of dopaminergic input in PD. In addition, PET studies of human subjects with a chronic history of cocaine abuse have revealed a reduction in D 2/3 receptors relative to age-matched controls. 31 for developing D 2 -selective PET radiotracers. In these earlier studies, we prepared a number of structural analogs of the classical D 2-like dopamine receptor antagonists, haloperidol, having a high affinity for D 2 versus D 3 receptors. 15, 16 In the current study, we focused on the atypical antipsychotic aripiprazole because this compound was reported to have a modest selectivity for D 2 versus D 3 . 39 We explored the possibility of preparing aripiprazole analogs that might have higher affinity and selectivity for D 2 versus D 3 receptors than that of aripiprazole itself. First, the N-2,3-dichlorophenyl piperazine ring of aripiprazole was replaced with amine groups present in typical antipsychotics such as haloperidol, benperidol, domperidone, and N-methylspiperone. The results of this study revealed that replacing the N-2,3-dichlorophenyl piperazine ring of aripiprazole with these amine groups did not result in useful ligands since compounds 2-5 had low binding affinity at D 2 , D 3 , and D 4 receptors. Second, we replaced the N-2,3-dichlorophenyl group of aripiprazole with N-2-methoxyphenyl group (compound 6) or N-2-(2-fluoroethoxy)phenyl group (compound 7). Compounds 6 and 7 bind at D 2 receptors with nanomolar affinity and have >50-fold selectivity for human D 2 receptors compared to human D 3 dopamine receptor subtype. These two analogs also bind with low affinity at the D 4 dopamine receptor subtype, as well as r 1 and r 2 receptors. These two analogs were evaluated for intrinsic efficacy and found to be partial agonists at both D 2 and D 3 receptors. Third, we changed the position of the methoxy group from the 2-position to the 4-position of the piperazine moiety. Compound 8 (with N-4-methoxyphenyl group) lost the binding affinity to both D 2 and D 3 receptors. Substitution on both 2-and 4-positions (compounds 9 and 10) decrease D 3 receptor affinity but had little effect on D 2 receptor affinity. Fourth, we also introduced a double bond into the tetrahydroisoquinoline ring of 6 and 7. Compounds 11 and 12 maintain a similar affinity for D 2 receptors with a slight increase in affinity for D 3 receptors. Finally, we changed the length of the carbon spacer in the chain between two ring systems of 6 and 11 from 4-carbon atoms to 3-carbon atoms (compounds 13 and 14) or 5-carbon chain (compounds 15 and 16). This change resulted in compounds with nanomolar affinity at both D 2 and D 3 receptors, resulting in a low selectivity for the two receptor subtypes.
The high affinity and good selectivity of compounds 6 and 7 for D 2 versus D 3 receptors indicate that they should be useful probes for studying the behavioral pharmacology of the D 2 receptor. Furthermore, these compounds can be easily radiolabeled with either carbon-11 (t 1/2 = 20.4 min) and fluorine-18 (t 1/2 = 109.7 min) and serve as useful PET radiotracers for measuring the density of D 2 receptors in the CNS without interference from labeling dopamine D 3 receptors. The lipophilicities (log P) of 6 and 7 ( Table 1 ) also suggest that they will readily cross the blood brain barrier and are good candidates for the development of D 2 receptor selective imaging agents for the functional imaging technique, PET. PET imaging studies with [ 11 C]6 and [ 18 F]7 are currently ongoing in our group and will be published separately. In summary, a series of structural congeners of aripiprazole were synthesized and evaluated for their affinities and efficacies at D 2 and D 3 receptors. The results of the in vitro binding studies have identified two compounds, 6 and 7, which will be useful probes for studying the function of the dopamine D 2 versus D 3 receptor in the CNS. P41RR0954 ). All reactions were carried out under an inert atmosphere of nitrogen. Lipophilicity measurements of the compounds were estimated using the computational program, C log P (Advanced Chemistry Development, Inc., Toronto, Canada).
7-(4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one oxalate (2)
A mixture of 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1H)-one (20, 1.7 mmol), 4-(chlorophenyl)-4-hydroxypiperidine (1.7 m mol), potassium carbonate (5 equiv) and potassium iodide (1 equiv) in acetonitrile (20 mL) was stirred at reflux overnight. The reaction mixture was evaporated. The resulting residue was suspended in water (25 mL) and filtered. The solid was washed with water and air dried to give the product as white powder (96% yield). The oxalate salt was prepared using 1 equiv of oxalic acid in ethanol and recrystallized from ethanol to give 2 as an off-white powder, mp 178-179°C; 1 
7-(4-(4-(
Compound 3 was synthesized as described for 2, from 4-(2-keto-1-benzimidazolinyl)piperidine in 67% yield. Conversion 7.8. 7-(4-(4-(2-(2-Fluoroethoxy)phenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one oxalate (7) 1-Bromo-2-fluoroethane (5.0 mmol) and potassium carbonate (4 equiv) were added into the solution of 17 (1.5 mmol) in acetone (15 mL). The reaction mixture was heated at 65-70°C for 48 h. The solid was filtered off and washed with acetone. The filtrate was evaporated. The resulting residue was purified by silica gel column chromatography (5% methanol in dichloromethane) to give the product (59% yield). Conversion to the oxalate salt gave 7 as an off-white powder, mp 147-148°C; Compound 9 was synthesized as described for 2, from 1-(2,4-dimethoxyphenyl)piperazine hydrochloride in 71% yield. Conversion to the oxalate salt gave 9 as an off-white powder, mp 167-168°C; A mixture of 7-(4-bromobutoxy)quinolin-2(1H)-one 17 (21, 0.78 mmol), 1-(2-methoxyphenyl)piperazine hydrochloride (1.00 mmol), and triethylamine (0.5 mL) in acetonitrile (15 mL) was refluxed overnight. The solvent was evaporated under reduced pressure. The residue was dissolved in dichloromethane, washed with saturated NaHCO 3 solution, dried over Na 2 SO 4 , concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (5% methanol in dichloromethane) to give the product as an oil (62% yield). Conversion to the oxalate salt gave 11 as an off-white powder, mp 180-182°C; 1 A mixture of 15 (0.28 mmol), and DDQ (0.34 mmol) in dichloromethane (5 mL) was stirred at room temperature overnight. The mixture was washed with saturated NaHCO 3 solution, dried, and concentrated in vacuo. The residue was purified by column chromatography (5% methanol in dichloromethane) to give the product as a free base in 75% yield. Conversion to oxalate salt gave 16 as a white powder; mp 229-230°C. I-IABN using peracetic acid has been previously described. 23 For radioligand binding studies, I-labeled ligand was quantitated using a Packard Cobra gamma counter with an efficiency of 75%. Protein concentrations were determined using a BCA reagent (Pierce, Rockford, Illinois) with bovine serum albumin as the protein standard.
For competition curves using a transfected cell line expressing D 2 , D 3 , or D 4 dopamine receptors, experiments were performed in triplicate with two concentrations of inhibitor per decade over at least five orders of magnitude. The concentration of the radioligand was approximately equal to the K d values. Controls containing either no inhibitor or 2 lM (+)-butaclamol were used to define total binding and nonspecific binding, respectively. Competition data for D 2-like dopamine receptors were modeled for a single-site fit using the TABLECURVE program (Jandel Scientific Software, San Rafael, California); the IC 50 values for the competitive inhibitors were converted to K i values using the Cheng and Prusoff corrections. 40 
Sigma receptor binding assays
Test compounds were dissolved in N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO) or ethanol and then diluted in 50 mM Tris-HCl buffer, pH 7.4, containing 150 mM NaCl and 100 mM EDTA. Membrane homogenates were made from guinea pig brain for r 1 binding assay and rat liver for r 2 binding assay.
Membrane homogenates were diluted with 50 mM Tris-HCl buffer, pH 8.0, and incubated at 25°C in a total volume of 150 lL in 96-well plates with the radioligand and test compounds with concentrations ranging from 0.1 nM to 10 lM. After incubation was completed, the reactions were terminated by the addition of 150 lL of ice-cold wash buffer (10 mM Tris-HCl, 150 mM NaCl, pH 7.4) using a 96-channel transfer pipette (Fisher Scientific, Pittsburgh, PA), and the samples
